1
|
Leusmann S, Ménová P, Shanin E, Titz A, Rademacher C. Glycomimetics for the inhibition and modulation of lectins. Chem Soc Rev 2023; 52:3663-3740. [PMID: 37232696 PMCID: PMC10243309 DOI: 10.1039/d2cs00954d] [Citation(s) in RCA: 23] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2022] [Indexed: 05/27/2023]
Abstract
Carbohydrates are essential mediators of many processes in health and disease. They regulate self-/non-self- discrimination, are key elements of cellular communication, cancer, infection and inflammation, and determine protein folding, function and life-times. Moreover, they are integral to the cellular envelope for microorganisms and participate in biofilm formation. These diverse functions of carbohydrates are mediated by carbohydrate-binding proteins, lectins, and the more the knowledge about the biology of these proteins is advancing, the more interfering with carbohydrate recognition becomes a viable option for the development of novel therapeutics. In this respect, small molecules mimicking this recognition process become more and more available either as tools for fostering our basic understanding of glycobiology or as therapeutics. In this review, we outline the general design principles of glycomimetic inhibitors (Section 2). This section is then followed by highlighting three approaches to interfere with lectin function, i.e. with carbohydrate-derived glycomimetics (Section 3.1), novel glycomimetic scaffolds (Section 3.2) and allosteric modulators (Section 3.3). We summarize recent advances in design and application of glycomimetics for various classes of lectins of mammalian, viral and bacterial origin. Besides highlighting design principles in general, we showcase defined cases in which glycomimetics have been advanced to clinical trials or marketed. Additionally, emerging applications of glycomimetics for targeted protein degradation and targeted delivery purposes are reviewed in Section 4.
Collapse
Affiliation(s)
- Steffen Leusmann
- Chemical Biology of Carbohydrates (CBCH), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, 66123 Saarbrücken, Germany.
- Department of Chemistry, Saarland University, 66123 Saarbrücken, Germany
- Deutsches Zentrum für Infektionsforschung (DZIF), Standort Hannover-Braunschweig, Germany
| | - Petra Ménová
- University of Chemistry and Technology, Prague, Technická 5, 16628 Prague 6, Czech Republic
| | - Elena Shanin
- Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
- Department of Microbiology, Immunobiology and Genetics, Max F. Perutz Laboratories, University of Vienna, Biocenter 5, 1030 Vienna, Austria
| | - Alexander Titz
- Chemical Biology of Carbohydrates (CBCH), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, 66123 Saarbrücken, Germany.
- Department of Chemistry, Saarland University, 66123 Saarbrücken, Germany
- Deutsches Zentrum für Infektionsforschung (DZIF), Standort Hannover-Braunschweig, Germany
| | - Christoph Rademacher
- Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
- Department of Microbiology, Immunobiology and Genetics, Max F. Perutz Laboratories, University of Vienna, Biocenter 5, 1030 Vienna, Austria
| |
Collapse
|
2
|
Tessema FB, Gonfa YH, Asfaw TB, Tadesse TG, Tadesse MG, Bachheti A, Pandey DP, Wabaidur SM, Dahlous KA, Širić I, Kumar P, Kumar V, Abou Fayssal S, Bachheti RK. Flavonoids and Phenolic Acids from Aerial Part of Ajuga integrifolia (Buch.-Ham. Ex D. Don): Anti-Shigellosis Activity and In Silico Molecular Docking Studies. Molecules 2023; 28:molecules28031111. [PMID: 36770779 PMCID: PMC9920895 DOI: 10.3390/molecules28031111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Revised: 01/11/2023] [Accepted: 01/18/2023] [Indexed: 01/24/2023] Open
Abstract
Shigellosis is one of the major causes of death in children worldwide. Flavonoids and phenolic acids are expected to demonstrate anti-shigellosis activity and anti-diarrheal properties. The aerial part of A. integrifolia is commonly used against diarrhea. This study aimed to identify flavonoids and phenolic acids responsible for this therapeutic purpose. Antioxidant activity, total phenol content, and total flavonoid content were determined. The antibacterial activity of the aerial part against Shigella spp. was also tested using the agar well diffusion method. HPLC analysis was performed using UHPLC-DAD for different extracts of the aerial part. Autodock Vina in the PyRx platform was used to screen responsible components. Ciprofloxacin was used as a reference drug. An enzyme taking part in pyrimidine biosynthesis was used as a target protein. Molecular docking results were visualized using Discovery Studio and LigPlot1.4.5 software. Antioxidant activity, total phenol content, and total flavonoid content are more significant for the aerial part of A. integrifolia. From HPLC analysis, the presence of the flavonoids, quercetin, myricetin, and rutin and the phenolic acids gallic acid, chlorogenic acid, and syringic acid were identified from the aerial part of A. integrifolia. Regarding the antibacterial activity, the aerial part shows considerable activity against Shigella spp. Binding energies, RMSD and Ki values, interaction type, and distance are considered to identify the components most likely responsible for the therapeutic effects and observed activity. Antioxidant activity, total phenol content, and total flavonoid content of the aerial part are in line with anti-shigellosis activity. The top five components that are most likely potentially responsible for therapeutic purposes and anti-shigellosis activity are chlorogenic acid, rutin, dihydroquercetin, dihydromyricetin, and kaempferol.
Collapse
Affiliation(s)
- Fekade Beshah Tessema
- Department of Industrial Chemistry, Addis Ababa Science and Technology University, Addis Ababa 16417, Ethiopia
- Department of Chemistry, Faculty of Natural and Computational Science, Woldia University, Woldia 400, Ethiopia
| | - Yilma Hunde Gonfa
- Department of Industrial Chemistry, Addis Ababa Science and Technology University, Addis Ababa 16417, Ethiopia
- Department of Chemistry, Faculty of Natural and Computational Science, Ambo University, Ambo 19, Ethiopia
| | - Tilahun Belayneh Asfaw
- Department of Industrial Chemistry, Addis Ababa Science and Technology University, Addis Ababa 16417, Ethiopia
- Department of Chemistry, College of Natural and Computational Science, Gondar University, Gondar 196, Ethiopia
| | - Tigist Getachew Tadesse
- Bio and Emerging Technology Institute, Health Biotechnology Directorate, Addis Ababa 5954, Ethiopia
| | - Mesfin Getachew Tadesse
- Department of Industrial Chemistry, Addis Ababa Science and Technology University, Addis Ababa 16417, Ethiopia
| | - Archana Bachheti
- Department of Environment Science, Graphic Era (Deemed to be University), Dehradun 248002, India
| | - Devi Prasad Pandey
- Department of Chemistry, Govt Degree College Dehradun Shahar, Suddhowala, Dehradun 248007, India
| | - Saikh M. Wabaidur
- Department of Chemistry, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
| | - Kholood A. Dahlous
- Department of Chemistry, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
| | - Ivan Širić
- University of Zagreb, Faculty of Agriculture, Svetosimunska 25, Zagreb 10000, Croatia
| | - Pankaj Kumar
- Agro-Ecology and Pollution Research Laboratory, Department of Zoology and Environmental Science, Gurukula Kangri (Deemed to be University), Haridwar 249404, India
| | - Vinod Kumar
- Agro-Ecology and Pollution Research Laboratory, Department of Zoology and Environmental Science, Gurukula Kangri (Deemed to be University), Haridwar 249404, India
| | - Sami Abou Fayssal
- Department of Agronomy, Faculty of Agronomy, University of Forestry, 10 Kliment Ohridski Blvd, 1797 Sofia, Bulgaria
- Department of Plant Production, Faculty of Agriculture, Lebanese University, Beirut 1302, Lebanon
| | - Rakesh Kumar Bachheti
- Department of Industrial Chemistry, Addis Ababa Science and Technology University, Addis Ababa 16417, Ethiopia
- Centre of Excellence in Biotechnology and Bioprocess, Addis Ababa Science and Technology University, Addis Ababa 16417, Ethiopia
- Correspondence:
| |
Collapse
|
3
|
Zhang X, Yu S, Liu Z, Long Y, Zhao J, Xu W, Zhang H, Zhang H. Development of a Kilogram-Scale Route for Clinical Sample Production of the Intravenous Anesthetic Cipepofol. Org Process Res Dev 2022. [DOI: 10.1021/acs.oprd.1c00306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Xiaowei Zhang
- Sichuan Haisco Pharmaceutical Co. Ltd., 136 Baili Road, Wenjiang District, Chengdu 611130, China
| | - Shuowen Yu
- Sichuan Haisco Pharmaceutical Co. Ltd., 136 Baili Road, Wenjiang District, Chengdu 611130, China
| | - Zhaojun Liu
- Sichuan Haisco Pharmaceutical Co. Ltd., 136 Baili Road, Wenjiang District, Chengdu 611130, China
| | - Yuanqiang Long
- Sichuan Haisco Pharmaceutical Co. Ltd., 136 Baili Road, Wenjiang District, Chengdu 611130, China
| | - Jinwei Zhao
- Sichuan Haisco Pharmaceutical Co. Ltd., 136 Baili Road, Wenjiang District, Chengdu 611130, China
| | - Wei Xu
- Sichuan Haisco Pharmaceutical Co. Ltd., 136 Baili Road, Wenjiang District, Chengdu 611130, China
| | - Haifeng Zhang
- Sichuan Haisco Pharmaceutical Co. Ltd., 136 Baili Road, Wenjiang District, Chengdu 611130, China
| | - Haijun Zhang
- Sichuan Haisco Pharmaceutical Co. Ltd., 136 Baili Road, Wenjiang District, Chengdu 611130, China
| |
Collapse
|
4
|
Wong DJ, Park DD, Park SS, Haller CA, Chen J, Dai E, Liu L, Mandhapati AR, Eradi P, Dhakal B, Wever WJ, Hanes M, Sun L, Cummings RD, Chaikof EL. A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis. Blood 2021; 138:1182-1193. [PMID: 33945603 PMCID: PMC8570056 DOI: 10.1182/blood.2020009428] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Accepted: 04/19/2021] [Indexed: 11/20/2022] Open
Abstract
Events mediated by the P-selectin/PSGL-1 pathway play a critical role in the initiation and propagation of venous thrombosis by facilitating the accumulation of leukocytes and platelets within the growing thrombus. Activated platelets and endothelium express P-selectin, which binds P-selectin glycoprotein ligand-1 (PSGL-1) that is expressed on the surface of all leukocytes. We developed a pegylated glycomimetic of the N terminus of PSGL-1, PEG40-GSnP-6 (P-G6), which proved to be a highly potent P-selectin inhibitor with a favorable pharmacokinetic profile for clinical translation. P-G6 inhibits human and mouse platelet-monocyte and platelet-neutrophil aggregation in vitro and blocks microcirculatory platelet-leukocyte interactions in vivo. Administration of P-G6 reduces thrombus formation in a nonocclusive model of deep vein thrombosis with a commensurate reduction in leukocyte accumulation, but without disruption of hemostasis. P-G6 potently inhibits the P-selectin/PSGL-1 pathway and represents a promising drug candidate for the prevention of venous thrombosis without increased bleeding risk.
Collapse
Affiliation(s)
- Daniel J Wong
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Diane D Park
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Simon S Park
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Carolyn A Haller
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Jiaxuan Chen
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Erbin Dai
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Liying Liu
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Appi R Mandhapati
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Pradheep Eradi
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Bibek Dhakal
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Walter J Wever
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Melinda Hanes
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Lijun Sun
- Center for Drug Discovery and Translational Research, Department of Surgery, Beth Israel Deaconess Medical Center and
| | - Richard D Cummings
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
- Harvard Medical School Center for Glycoscience, Harvard Medical School, Boston, MA
| | - Elliot L Chaikof
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| |
Collapse
|
5
|
Šmak P, Chandrabose S, Tvaroška I, Koča J. Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study. Glycobiology 2021; 31:975-987. [PMID: 33822042 PMCID: PMC8083503 DOI: 10.1093/glycob/cwab021] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Revised: 03/06/2021] [Accepted: 03/06/2021] [Indexed: 12/15/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19) has spread rapidly throughout the globe. The spectrum of disease is broad but among hospitalized patients with COVID-19, respiratory failure from acute respiratory distress syndrome is the leading cause of mortality. There is an urgent need for an effective treatment. The current focus has been developing novel therapeutics, including antivirals, protease inhibitors, vaccines and targeting the overactive cytokine response with anti-cytokine therapy. The overproduction of early response proinflammatory cytokines results in what has been described as a "cytokine storm" is leading eventually to death when the cells fail to terminate the inflammatory response. Accumulating evidence shows that inflammatory cytokines induce selectin ligands that play a crucial role in the pathogenesis of inflammatory diseases by mediating leukocyte migration from the blood into the tissue. Thus, the selectins and selectin ligands represent a promising therapeutic target for the treatment of COVID-19. In this paper, potential pan-selectin inhibitors were identified employing a virtual screening using a docking procedure. For this purpose, the Asinex and ZINC databases of ligands, including approved drugs, biogenic compounds and glycomimetics, altogether 923,602 compounds, were screened against the P-, L- and E-selectin. At first, the experimentally confirmed inhibitors were docked into all three selectins' carbohydrate recognition domains to assess the suitability of the screening procedure. Finally, based on the evaluation of ligands binding, we propose 10 purchasable pan-selectin inhibitors to develop COVID-19 therapeutics.
Collapse
Affiliation(s)
- Pavel Šmak
- National Centre for Biomolecular Research, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
| | - Selvaraj Chandrabose
- Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic
| | - Igor Tvaroška
- National Centre for Biomolecular Research, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
- Institute of Chemistry, Slovak Academy of Sciences, 845 38 Bratislava, Slovak Republic
| | - Jaroslav Koča
- National Centre for Biomolecular Research, Faculty of Science, Masaryk University, 625 00 Brno, Czech Republic
- Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic
| |
Collapse
|
6
|
Kuhaudomlarp S, Siebs E, Shanina E, Topin J, Joachim I, da Silva Figueiredo Celestino Gomes P, Varrot A, Rognan D, Rademacher C, Imberty A, Titz A. Non-Carbohydrate Glycomimetics as Inhibitors of Calcium(II)-Binding Lectins. Angew Chem Int Ed Engl 2021; 60:8104-8114. [PMID: 33314528 PMCID: PMC8048816 DOI: 10.1002/anie.202013217] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Indexed: 12/21/2022]
Abstract
Because of the antimicrobial resistance crisis, lectins are considered novel drug targets. Pseudomonas aeruginosa utilizes LecA and LecB in the infection process. Inhibition of both lectins with carbohydrate-derived molecules can reduce biofilm formation to restore antimicrobial susceptibility. Here, we focused on non-carbohydrate inhibitors for LecA to explore new avenues for lectin inhibition. From a screening cascade we obtained one experimentally confirmed hit, a catechol, belonging to the well-known PAINS compounds. Rigorous analyses validated electron-deficient catechols as millimolar LecA inhibitors. The first co-crystal structure of a non-carbohydrate inhibitor in complex with a bacterial lectin clearly demonstrates the catechol mimicking the binding of natural glycosides with LecA. Importantly, catechol 3 is the first non-carbohydrate lectin ligand that binds bacterial and mammalian calcium(II)-binding lectins, giving rise to this fundamentally new class of glycomimetics.
Collapse
Affiliation(s)
| | - Eike Siebs
- Chemical Biology of Carbohydrates (CBCH)Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Centre for Infection Research66123SaarbrückenGermany
- Department of ChemistrySaarland University66123SaarbrückenGermany
- Deutsches Zentrum für Infektionsforschung (DZIF)Hannover-BraunschweigGermany
| | - Elena Shanina
- Department of Biomolecular SystemsMax Planck Institute of Colloids and Interfaces14424PotsdamGermany
- Institute of Chemistry and BiochemistryDepartment of Biology, Chemistry and PharmacyFreie Universität Berlin14195BerlinGermany
| | - Jérémie Topin
- Université Grenoble AlpesCNRSCERMAV38000GrenobleFrance
- Institute of Chemistry-NiceUMR 7272 CNRSUniversité Côte d'Azur06108NiceFrance
| | - Ines Joachim
- Chemical Biology of Carbohydrates (CBCH)Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Centre for Infection Research66123SaarbrückenGermany
- Department of ChemistrySaarland University66123SaarbrückenGermany
- Deutsches Zentrum für Infektionsforschung (DZIF)Hannover-BraunschweigGermany
| | | | | | - Didier Rognan
- Laboratoire d'Innovation ThérapeutiqueUMR 7200 CNRS-Université de Strasbourg67400IllkirchFrance
| | - Christoph Rademacher
- Department of Biomolecular SystemsMax Planck Institute of Colloids and Interfaces14424PotsdamGermany
- Institute of Chemistry and BiochemistryDepartment of Biology, Chemistry and PharmacyFreie Universität Berlin14195BerlinGermany
| | - Anne Imberty
- Université Grenoble AlpesCNRSCERMAV38000GrenobleFrance
| | - Alexander Titz
- Chemical Biology of Carbohydrates (CBCH)Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)Helmholtz Centre for Infection Research66123SaarbrückenGermany
- Department of ChemistrySaarland University66123SaarbrückenGermany
- Deutsches Zentrum für Infektionsforschung (DZIF)Hannover-BraunschweigGermany
| |
Collapse
|
7
|
Kuhaudomlarp S, Siebs E, Shanina E, Topin J, Joachim I, Silva Figueiredo Celestino Gomes P, Varrot A, Rognan D, Rademacher C, Imberty A, Titz A. Non‐Carbohydrate Glycomimetics as Inhibitors of Calcium(II)‐Binding Lectins. Angew Chem Int Ed Engl 2021. [DOI: 10.1002/ange.202013217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
| | - Eike Siebs
- Chemical Biology of Carbohydrates (CBCH) Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) Helmholtz Centre for Infection Research 66123 Saarbrücken Germany
- Department of Chemistry Saarland University 66123 Saarbrücken Germany
- Deutsches Zentrum für Infektionsforschung (DZIF) Hannover-Braunschweig Germany
| | - Elena Shanina
- Department of Biomolecular Systems Max Planck Institute of Colloids and Interfaces 14424 Potsdam Germany
- Institute of Chemistry and Biochemistry Department of Biology, Chemistry and Pharmacy Freie Universität Berlin 14195 Berlin Germany
| | - Jérémie Topin
- Université Grenoble Alpes CNRS CERMAV 38000 Grenoble France
- Institute of Chemistry-Nice UMR 7272 CNRS Université Côte d'Azur 06108 Nice France
| | - Ines Joachim
- Chemical Biology of Carbohydrates (CBCH) Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) Helmholtz Centre for Infection Research 66123 Saarbrücken Germany
- Department of Chemistry Saarland University 66123 Saarbrücken Germany
- Deutsches Zentrum für Infektionsforschung (DZIF) Hannover-Braunschweig Germany
| | | | | | - Didier Rognan
- Laboratoire d'Innovation Thérapeutique UMR 7200 CNRS-Université de Strasbourg 67400 Illkirch France
| | - Christoph Rademacher
- Department of Biomolecular Systems Max Planck Institute of Colloids and Interfaces 14424 Potsdam Germany
- Institute of Chemistry and Biochemistry Department of Biology, Chemistry and Pharmacy Freie Universität Berlin 14195 Berlin Germany
| | - Anne Imberty
- Université Grenoble Alpes CNRS CERMAV 38000 Grenoble France
| | - Alexander Titz
- Chemical Biology of Carbohydrates (CBCH) Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) Helmholtz Centre for Infection Research 66123 Saarbrücken Germany
- Department of Chemistry Saarland University 66123 Saarbrücken Germany
- Deutsches Zentrum für Infektionsforschung (DZIF) Hannover-Braunschweig Germany
| |
Collapse
|
8
|
Tvaroška I, Selvaraj C, Koča J. Selectins-The Two Dr. Jekyll and Mr. Hyde Faces of Adhesion Molecules-A Review. Molecules 2020; 25:molecules25122835. [PMID: 32575485 PMCID: PMC7355470 DOI: 10.3390/molecules25122835] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Revised: 05/27/2020] [Accepted: 06/17/2020] [Indexed: 02/06/2023] Open
Abstract
Selectins belong to a group of adhesion molecules that fulfill an essential role in immune and inflammatory responses and tissue healing. Selectins are glycoproteins that decode the information carried by glycan structures, and non-covalent interactions of selectins with these glycan structures mediate biological processes. The sialylated and fucosylated tetrasaccharide sLex is an essential glycan recognized by selectins. Several glycosyltransferases are responsible for the biosynthesis of the sLex tetrasaccharide. Selectins are involved in a sequence of interactions of circulated leukocytes with endothelial cells in the blood called the adhesion cascade. Recently, it has become evident that cancer cells utilize a similar adhesion cascade to promote metastases. However, like Dr. Jekyll and Mr. Hyde’s two faces, selectins also contribute to tissue destruction during some infections and inflammatory diseases. The most prominent function of selectins is associated with the initial stage of the leukocyte adhesion cascade, in which selectin binding enables tethering and rolling. The first adhesive event occurs through specific non-covalent interactions between selectins and their ligands, with glycans functioning as an interface between leukocytes or cancer cells and the endothelium. Targeting these interactions remains a principal strategy aimed at developing new therapies for the treatment of immune and inflammatory disorders and cancer. In this review, we will survey the significant contributions to and the current status of the understanding of the structure of selectins and the role of selectins in various biological processes. The potential of selectins and their ligands as therapeutic targets in chronic and acute inflammatory diseases and cancer will also be discussed. We will emphasize the structural characteristic of selectins and the catalytic mechanisms of glycosyltransferases involved in the biosynthesis of glycan recognition determinants. Furthermore, recent achievements in the synthesis of selectin inhibitors will be reviewed with a focus on the various strategies used for the development of glycosyltransferase inhibitors, including substrate analog inhibitors and transition state analog inhibitors, which are based on knowledge of the catalytic mechanism.
Collapse
Affiliation(s)
- Igor Tvaroška
- Central European Institute of Technology (CEITEC), Masaryk University, 62500 Brno, Czech Republic
- Institute of Chemistry, Slovak Academy of Sciences, 84538 Bratislava, Slovak Republic
- Correspondence: (I.T.); (J.K.); Tel.: +421-948-535-601 (I.T.); +420-731-682-606 (J.K.)
| | - Chandrabose Selvaraj
- Central European Institute of Technology (CEITEC), Masaryk University, 62500 Brno, Czech Republic
| | - Jaroslav Koča
- Central European Institute of Technology (CEITEC), Masaryk University, 62500 Brno, Czech Republic
- National Centre for Biomolecular Research, Faculty of Science, Masaryk University, 62500 Brno, Czech Republic
- Correspondence: (I.T.); (J.K.); Tel.: +421-948-535-601 (I.T.); +420-731-682-606 (J.K.)
| |
Collapse
|
9
|
Naik B, Gupta N, Ojha R, Singh S, Prajapati VK, Prusty D. High throughput virtual screening reveals SARS-CoV-2 multi-target binding natural compounds to lead instant therapy for COVID-19 treatment. Int J Biol Macromol 2020; 160:1-17. [PMID: 32470577 PMCID: PMC7250083 DOI: 10.1016/j.ijbiomac.2020.05.184] [Citation(s) in RCA: 61] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Revised: 05/21/2020] [Accepted: 05/22/2020] [Indexed: 12/21/2022]
Abstract
The present-day world is severely suffering from the recently emerged SARS-CoV-2. The lack of prescribed drugs for the deadly virus has stressed the likely need to identify novel inhibitors to alleviate and stop the pandemic. In the present high throughput virtual screening study, we used in silico techniques like receptor-ligand docking, Molecular dynamic (MD), and ADME properties to screen natural compounds. It has been documented that many natural compounds display antiviral activities, including anti–SARS-CoV effect. The present study deals with compounds of Natural Product Activity and Species Source (NPASS) database with known biological activity that probably impedes the activity of six essential enzymes of the virus. Promising drug-like compounds were identified, demonstrating better docking score and binding energy for each druggable targets. After an extensive screening analysis, three novel multi-target natural compounds were predicted to subdue the activity of three/more major drug targets simultaneously. Concerning the utility of natural compounds in the formulation of many therapies, we propose these compounds as excellent lead candidates for the development of therapeutic drugs against SARS-CoV-2.
Collapse
Affiliation(s)
- Biswajit Naik
- Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, 305817 Ajmer, Rajasthan, India
| | - Nidhi Gupta
- Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, 305817 Ajmer, Rajasthan, India
| | - Rupal Ojha
- Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, 305817 Ajmer, Rajasthan, India
| | - Satyendra Singh
- Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, 305817 Ajmer, Rajasthan, India
| | - Vijay Kumar Prajapati
- Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, 305817 Ajmer, Rajasthan, India
| | - Dhaneswar Prusty
- Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, NH-8, Bandarsindri, Kishangarh, 305817 Ajmer, Rajasthan, India.
| |
Collapse
|
10
|
Attenuation of neutrophil-mediated liver injury in mice by drug-free E-selectin binding polymer. J Control Release 2019; 319:475-486. [PMID: 31838202 DOI: 10.1016/j.jconrel.2019.12.018] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2019] [Revised: 12/06/2019] [Accepted: 12/11/2019] [Indexed: 12/12/2022]
Abstract
Inflammation with neutrophils infiltration is a prominent feature of alcohol-related liver disease (ARLD) and contributes to the severity of liver injury. Although an array of potential treatments has been studied, the standard treatment regimen is controversial and can induce severe side effects and infection-related complications. E-selectin, a cytokine inducible cell adhesion molecule, mediates the initial interaction of leucocytes with endothelial cells, and facilitates their further adhesion and extravasation into inflamed tissues. Given the important role of E-selectin in leukocytes trafficking, we hypothesized that a synthetic polymer presenting multiple copies of E-selectin binding peptide in a polyvalent manner (P-Esbp) may block the "roads" that facilitate neutrophil infiltration, inhibit the recruitment of neutrophils to the inflamed sites and reduce the extent of liver injury. We now demonstrate in vitro that P-Esbp reduced the recruitment of neutrophils (collected from blood of donors) on activated human umbilical vein endothelial cells (HUVEC) under flow conditions. Pre-treatment of mice with P-Esbp prior to alcohol binge attenuated alcohol-induced serum transaminase (ALT, AST) elevation, reduced pro-inflammatory cytokines (TNFα and IL-1ẞ) and chemokines (MIP-2/CXCL2 and MCP-1/CCL2) in National Institute on Alcohol Abuse and Alcoholism (NIAAA) model. Also, the up-regulation of neutrophil marker Ly6G and the number of MPO positive cells in the injured tissue was significantly reduced by the treatment, indicating diminished neutrophil infiltration. Moreover, as a result of P-Esbp treatment, E-selectin expression in the liver (mRNA and protein level) was downregulated, suggesting a potential to decrease ongoing local inflammatory response. Overall, our findings highlight the anti-inflammatory properties of the "drug-free" P-Esbp and its therapeutic potential to attenuate an excessive inflammation where infiltrating neutrophils can damage tissues and organs.
Collapse
|
11
|
Simard RD, Joyal M, Gillard L, Di Censo G, Maharsy W, Beauregard J, Colarusso P, Patel KD, Prévost M, Nemer M, Guindon Y. Synthesis of Sialyl Lewis X Glycomimetics Bearing a Bicyclic 3- O,4- C-Fused Galactopyranoside Scaffold. J Org Chem 2019; 84:7372-7387. [PMID: 31088084 DOI: 10.1021/acs.joc.9b01075] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Reported herein is the synthesis of sialyl LewisX analogues bearing a trans-bicyclo[4.4.0] dioxadecane-modified 3- O,4- C-fused galactopyranoside scaffold that locks the carboxylate pharmacophore in either the axial or equatorial position. This novel series of bicyclic galactopyranosides are prepared through a stereocontrolled intramolecular cyclization reaction that has been evaluated both experimentally and by density functional theory calculations. The cyclization precursors are obtained from β-d-galactose pentaacetate in a nine-step sequence featuring a highly diastereoselective equatorial alkynylation and Cu(I) catalyzed formation of the acetylenic α-ketoester moiety. Preliminary biological evaluations indicate improved activity as P-selectin antagonists for the axially configured analogues as compared to their equatorial counterparts.
Collapse
Affiliation(s)
- Ryan D Simard
- Bio-Organic Chemistry Laboratory , Institut de Recherches Cliniques de Montréal , Montréal , Québec H2W 1R7 , Canada.,Department of Chemistry , Université de Montréal , Montréal , Québec H3C 3J7 , Canada
| | - Mathieu Joyal
- Department of Biochemistry, Microbiology and Immunology , University of Ottawa , Ottawa , Ontario K1N 6N5 , Canada
| | - Laura Gillard
- Bio-Organic Chemistry Laboratory , Institut de Recherches Cliniques de Montréal , Montréal , Québec H2W 1R7 , Canada
| | - Gianna Di Censo
- Bio-Organic Chemistry Laboratory , Institut de Recherches Cliniques de Montréal , Montréal , Québec H2W 1R7 , Canada
| | - Wael Maharsy
- Department of Biochemistry, Microbiology and Immunology , University of Ottawa , Ottawa , Ontario K1N 6N5 , Canada
| | - Janie Beauregard
- Department of Biochemistry, Microbiology and Immunology , University of Ottawa , Ottawa , Ontario K1N 6N5 , Canada
| | - Pina Colarusso
- Live Cell Imaging Laboratory, Snyder Institute for Chronic Diseases , University of Calgary , Calgary , Alberta T2N 4N1 , Canada
| | - Kamala D Patel
- Live Cell Imaging Laboratory, Snyder Institute for Chronic Diseases , University of Calgary , Calgary , Alberta T2N 4N1 , Canada
| | - Michel Prévost
- Bio-Organic Chemistry Laboratory , Institut de Recherches Cliniques de Montréal , Montréal , Québec H2W 1R7 , Canada
| | - Mona Nemer
- Department of Biochemistry, Microbiology and Immunology , University of Ottawa , Ottawa , Ontario K1N 6N5 , Canada
| | - Yvan Guindon
- Bio-Organic Chemistry Laboratory , Institut de Recherches Cliniques de Montréal , Montréal , Québec H2W 1R7 , Canada.,Department of Chemistry , Université de Montréal , Montréal , Québec H3C 3J7 , Canada.,Department of Biochemistry, Microbiology and Immunology , University of Ottawa , Ottawa , Ontario K1N 6N5 , Canada
| |
Collapse
|
12
|
Tsoref O, Tyomkin D, Amit U, Landa N, Cohen-Rosenboim O, Kain D, Golan M, Naftali-Shani N, David A, Leor J. E-selectin-targeted copolymer reduces atherosclerotic lesions, adverse cardiac remodeling, and dysfunction. J Control Release 2018; 288:136-147. [DOI: 10.1016/j.jconrel.2018.08.029] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Revised: 08/15/2018] [Accepted: 08/20/2018] [Indexed: 01/08/2023]
|
13
|
Selectin catch-bonds mechanotransduce integrin activation and neutrophil arrest on inflamed endothelium under shear flow. Blood 2017; 130:2101-2110. [PMID: 28811304 DOI: 10.1182/blood-2017-05-783027] [Citation(s) in RCA: 60] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Accepted: 08/03/2017] [Indexed: 12/27/2022] Open
Abstract
E-selectin extends from the plasma membrane of inflamed endothelium and serves to capture leukocytes from flowing blood via long-lived catch-bonds that support slow leukocyte rolling under shear stress. Its ligands are glycosylated with the tetrasaccharide sialyl Lewisx (sLex), which contributes to bond affinity and specificity. E-selectin-mediated rolling transmits signals into neutrophils that trigger activation of high-affinity β2-integrins necessary for transition to shear-resistant adhesion and transendothelial migration. Rivipansel is a glycomimetic drug that inhibits E-selectin-mediated vaso-occlusion induced by integrin-dependent sickle-red blood cell-leukocyte adhesion. How Rivipansel antagonizes ligand recognition by E-selectin and blocks outside-in signaling of integrin-mediated neutrophil arrest while maintaining rolling immune-surveillance is unknown. Here, we demonstrate that sLex expressed on human L-selectin is preferentially bound by E-selectin and, on ligation, initiates secretion of MRP8/14 that binds TLR4 to elicit the extension of β2-integrin to an intermediate affinity state. Neutrophil rolling over E-selectin at precise shear stress transmits tension and catch-bond formation with L-selectin via sLex, resulting in focal clusters that deliver a distinct signal to upshift β2-integrins to a high-affinity state. Rivipansel effectively blocked formation of selectin catch-bonds, revealing a novel mechanotransduction circuit that rapidly converts extended β2-integrins to high-affinity shear-resistant bond clusters with intracellular adhesion molecule 1 on inflamed endothelium.
Collapse
|
14
|
Patel MS, Miranda-Nieves D, Chen J, Haller CA, Chaikof EL. Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome. Transl Res 2017; 183:1-13. [PMID: 28034759 PMCID: PMC5393932 DOI: 10.1016/j.trsl.2016.11.007] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2016] [Accepted: 11/13/2016] [Indexed: 12/22/2022]
Abstract
Obesity-induced insulin resistance and metabolic syndrome continue to pose an important public health challenge worldwide as they significantly increase the risk of type 2 diabetes and atherosclerotic cardiovascular disease. Advances in the pathophysiologic understanding of this process has identified that chronic inflammation plays a pivotal role. In this regard, given that both animal models and human studies have demonstrated that the interaction of P-selectin glycoprotein ligand-1 (PSGL-1) with P-selectin is not only critical for normal immune response but also is upregulated in the setting of metabolic syndrome, PSGL-1/P-selectin interactions provide a novel target for preventing and treating resultant disease. Current approaches of interfering with PSGL-1/P-selectin interactions include targeted antibodies, recombinant immunoglobulins that competitively bind P-selectin, and synthetic molecular therapies. Experimental models as well as clinical trials assessing the role of these modalities in a variety of diseases have continued to contribute to the understanding of PSGL-1/P-selectin interactions and have demonstrated the difficulty in creating clinically relevant therapeutics. Most recently, however, computational simulations have further enhanced our understanding of the structural features of PSGL-1 and related glycomimetics, which are responsible for high-affinity selectin interactions. Leveraging these insights for the design of next generation agents has thus led to development of a promising synthetic method for generating PSGL-1 glycosulfopeptide mimetics for the treatment of metabolic syndrome.
Collapse
Affiliation(s)
- Madhukar S Patel
- Department of Surgery, Massachusetts General Hospital, Boston, Mass; Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass
| | - David Miranda-Nieves
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass; Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Mass
| | - Jiaxuan Chen
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass
| | - Carolyn A Haller
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass
| | - Elliot L Chaikof
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Mass; Harvard Medical School, Boston, Mass.
| |
Collapse
|
15
|
Barra PA, Ribeiro AJM, Ramos MJ, Jiménez VA, Alderete JB, Fernandes PA. Binding free energy calculations on E-selectin complexes with sLex
oligosaccharide analogs. Chem Biol Drug Des 2016; 89:114-123. [DOI: 10.1111/cbdd.12837] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2016] [Revised: 08/01/2016] [Accepted: 08/06/2016] [Indexed: 02/03/2023]
Affiliation(s)
- Pabla A. Barra
- Departamento de Química Orgánica; Facultad de Ciencias Químicas; Universidad de Concepción; Concepción Chile
| | | | - Maria J. Ramos
- Faculdade de Ciencias; Universidad do Porto; Porto Portugal
| | - Verónica A. Jiménez
- Departamento de Ciencias Químicas; Facultad de Ciencias Exactas; Universidad Andres Bello Sede Concepción; Talcahuano Chile
| | - Joel B. Alderete
- Departamento de Química Orgánica; Facultad de Ciencias Químicas; Universidad de Concepción; Concepción Chile
| | | |
Collapse
|
16
|
Ishikawa K, Takeda H, Wakana D, Sato F, Hosoe T. Isolation and identification of berberine and berberrubine metabolites by berberine-utilizing bacterium Rhodococcus sp. strain BD7100. Biosci Biotechnol Biochem 2016; 80:856-62. [PMID: 26882131 DOI: 10.1080/09168451.2015.1136878] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Based on the finding of a novel berberine (BBR)-utilizing bacterium, Rhodococcus sp. strain BD7100, we investigated the degradation of BBR and its analog berberrubine (BRU). Resting cells of BD7100 demethylenated BBR and BRU, yielding benzeneacetic acid analogs. Isolation of benzeneacetic acid analogs suggested that BD7100 degraded the isoquinoline ring of the protoberberine skeleton. This work represents the first report of cleavage of protoberberine skeleton by a microorganism.
Collapse
Affiliation(s)
- Kazuki Ishikawa
- a Department of Organic Chemistry , Hoshi University , Tokyo , Japan
| | - Hisashi Takeda
- a Department of Organic Chemistry , Hoshi University , Tokyo , Japan
| | - Daigo Wakana
- a Department of Organic Chemistry , Hoshi University , Tokyo , Japan
| | - Fumihiko Sato
- b Division of Integrated Life Science, Graduate School of Biostudies , Kyoto University , Kyoto , Japan
| | - Tomoo Hosoe
- a Department of Organic Chemistry , Hoshi University , Tokyo , Japan
| |
Collapse
|
17
|
Hejchman E, Taciak P, Kowalski S, Maciejewska D, Czajkowska A, Borowska J, Śladowski D, Młynarczuk-Biały I. Synthesis and anticancer activity of 7-hydroxycoumarinyl gallates. Pharmacol Rep 2015; 67:236-44. [DOI: 10.1016/j.pharep.2014.09.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2014] [Revised: 09/11/2014] [Accepted: 09/12/2014] [Indexed: 12/24/2022]
|
18
|
Krishnamurthy VR, Sardar MYR, Ying Y, Song X, Haller C, Dai E, Wang X, Hanjaya-Putra D, Sun L, Morikis V, Simon SI, Woods RJ, Cummings RD, Chaikof EL. Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo. Nat Commun 2015; 6:6387. [PMID: 25824568 PMCID: PMC4423566 DOI: 10.1038/ncomms7387] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Accepted: 01/26/2015] [Indexed: 12/21/2022] Open
Abstract
Blockade of P-selectin/PSGL-1 interactions holds significant potential for treatment of disorders of innate immunity, thrombosis, and cancer. Current inhibitors remain limited due to low binding affinity or by the recognized disadvantages inherent to chronic administration of antibody therapeutics. Here we report an efficient approach for generating glycosulfopeptide mimics of N-terminal PSGL-1 through development of a stereoselective route for multi-gram scale synthesis of the C2 O-glycan building block and replacement of hydrolytically labile tyrosine sulfates with isosteric sulfonate analogs. Library screening afforded a compound of exceptional stability, GSnP-6, that binds to human P-selectin with nanomolar affinity (Kd ~ 22 nM). Molecular dynamics simulation defines the origin of this affinity in terms of a number of critical structural contributions. GSnP-6 potently blocks P-selectin/PSGL-1 interactions in vitro and in vivo and represents a promising candidate for the treatment of diseases driven by acute and chronic inflammation.
Collapse
Affiliation(s)
- Venkata R Krishnamurthy
- 1] Department of Surgery, Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 9F, Boston, Massachusetts 02215, USA [2] Wyss Institute of Biologically Inspired Engineering, Harvard University, 110 Francis Street, Suite 9F, Boston, Massachusetts 02115, USA
| | - Mohammed Y R Sardar
- 1] Department of Surgery, Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 9F, Boston, Massachusetts 02215, USA [2] Wyss Institute of Biologically Inspired Engineering, Harvard University, 110 Francis Street, Suite 9F, Boston, Massachusetts 02115, USA
| | - Yu Ying
- Department of Biochemistry, Emory University, Atlanta, Georgia 30322, USA
| | - Xuezheng Song
- Department of Biochemistry, Emory University, Atlanta, Georgia 30322, USA
| | - Carolyn Haller
- 1] Department of Surgery, Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 9F, Boston, Massachusetts 02215, USA [2] Wyss Institute of Biologically Inspired Engineering, Harvard University, 110 Francis Street, Suite 9F, Boston, Massachusetts 02115, USA
| | - Erbin Dai
- 1] Department of Surgery, Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 9F, Boston, Massachusetts 02215, USA [2] Wyss Institute of Biologically Inspired Engineering, Harvard University, 110 Francis Street, Suite 9F, Boston, Massachusetts 02115, USA
| | - Xiaocong Wang
- Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, USA
| | - Donny Hanjaya-Putra
- 1] Department of Surgery, Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 9F, Boston, Massachusetts 02215, USA [2] Wyss Institute of Biologically Inspired Engineering, Harvard University, 110 Francis Street, Suite 9F, Boston, Massachusetts 02115, USA
| | - Lijun Sun
- Department of Surgery, Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 9F, Boston, Massachusetts 02215, USA
| | - Vasilios Morikis
- Department of Biomedical Engineering, University of California Davis, Davis, California 95616, USA
| | - Scott I Simon
- Department of Biomedical Engineering, University of California Davis, Davis, California 95616, USA
| | - Robert J Woods
- 1] Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia 30602, USA [2] School of Chemistry, National University of Ireland, Galway, University Road, Galway, Ireland
| | - Richard D Cummings
- Department of Biochemistry, Emory University, Atlanta, Georgia 30322, USA
| | - Elliot L Chaikof
- 1] Department of Surgery, Center for Drug Discovery and Translational Research, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Suite 9F, Boston, Massachusetts 02215, USA [2] Wyss Institute of Biologically Inspired Engineering, Harvard University, 110 Francis Street, Suite 9F, Boston, Massachusetts 02115, USA
| |
Collapse
|
19
|
Huang Y, Wu D, Huang J, Guo Q, Li J, You J. Use of the Wilkinson Catalyst for theortho-CH Heteroarylation of Aromatic Amines: Facile Access to Highly Extended π-Conjugated Heteroacenes for Organic Semiconductors. Angew Chem Int Ed Engl 2014. [DOI: 10.1002/ange.201406445] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
20
|
Huang Y, Wu D, Huang J, Guo Q, Li J, You J. Use of the Wilkinson Catalyst for theortho-CH Heteroarylation of Aromatic Amines: Facile Access to Highly Extended π-Conjugated Heteroacenes for Organic Semiconductors. Angew Chem Int Ed Engl 2014; 53:12158-62. [DOI: 10.1002/anie.201406445] [Citation(s) in RCA: 81] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2014] [Indexed: 01/01/2023]
|
21
|
Small molecule inhibitors of protein interaction with glycosaminoglycans (SMIGs), a novel class of bioactive agents with anti-inflammatory properties. Biochim Biophys Acta Gen Subj 2013; 1840:245-54. [PMID: 24060749 DOI: 10.1016/j.bbagen.2013.09.023] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2013] [Revised: 09/12/2013] [Accepted: 09/16/2013] [Indexed: 11/22/2022]
Abstract
BACKGROUND Small molecule inhibitors of biologically important protein-glycosaminoglycan (GAG) interactions have yet to be identified. METHODS Compound libraries were screened in an assay of L-selectin-IgG binding to heparin (a species of heparan sulfate [HS-GAG]). Hits were validated, IC-50s established and direct binding of hits to HS-GAGs was investigated by incubating compounds alone with heparin. Selectivity of inhibitors was assessed in 11 different protein-GAG binding assays. Anti-inflammatory activity of selected compounds was evaluated in animal models. RESULTS Screening identified a number of structurally-diverse planar aromatic cationic amines. Scaffolds similar to known GAG binders, chloroquine and tilorone, were also identified. Inhibitors displayed activity also against bovine kidney heparan sulfate. Direct binding of compounds to GAGs was verified by incubating compounds with heparin alone. Selectivity of inhibitors was demonstrated in a panel of 11 heparin binding proteins, including selectins, chemokines (IL-8, IP-10), Beta Amyloid and cytokines (VEGF, IL-6). A number of selected lead compounds showed dose-dependent efficacy in peritonitis, paw edema and delayed type hypersensitivity. CONCLUSIONS A new class of compounds, SMIGs, inhibits protein-GAG interaction by direct binding to GAGs. Although their IC-50s were in the low micro-molar range, SMIGs binding to HS-GAGs appeared to be stable in physiological conditions, indicating high avidity binding. SMIGs may interfere with major checkpoints for inflammatory and autoimmune events. GENERAL SIGNIFICANCE SMIGs are a class of structurally-diverse planar aromatic cationic amines that have an unusual mode of action - inhibiting protein-GAG interactions via direct and stable binding to GAGs. SMIGs may have therapeutic potential in inflammatory and autoimmune disorders.
Collapse
|
22
|
Li Q, Yan TT, Niu S, Zhao YT, Meng XB, Zhao ZH, Li ZJ. Synthesis of a series of multivalent homo-, and heteroglycosides and their anti-adhesion activities. Carbohydr Res 2013; 379:78-94. [DOI: 10.1016/j.carres.2013.06.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2013] [Revised: 06/13/2013] [Accepted: 06/14/2013] [Indexed: 11/25/2022]
|
23
|
Azcune I, Balentová E, Sagartzazu-Aizpurua M, Ignacio Santos J, Miranda JI, Fratila RM, Aizpurua JM. Modulating Lectin Inhibition withN-Glycosyl-1,2,3-triazole Scaffolds. European J Org Chem 2013. [DOI: 10.1002/ejoc.201201674] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
24
|
Izgu EC, Hoye TR. o-(Trialkylstannyl)anilines and Their Utility in Stille Cross-Coupling: Direct Introduction of the 2-Aminophenyl Substituent. Tetrahedron Lett 2012; 53:4938-4941. [PMID: 22984300 DOI: 10.1016/j.tetlet.2012.06.138] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
We have developed shelf- and air-stable ortho-stannylated aniline reagents that can directly be coupled with alkenyl and aryl halides via Stille cross-coupling. We report i) the efficient preparation of o-(tributylstannyl)aniline (2a) and o-(trimethylstannyl)aniline (2b), ii) the comparison of the reactivities of 2a and 2b with those of related organostannanes in cross-coupling reaction with an alkenyl halide, and iii) the cross-coupling of 2a and 2b with a series of arylhalides and triflate.
Collapse
Affiliation(s)
- Enver Cagri Izgu
- Department of Chemistry, 207 Pleasant Street, SE, University of Minnesota, Minneapolis, Minnesota 55455
| | | |
Collapse
|
25
|
Bochkov DV, Sysolyatin SV, Kalashnikov AI, Surmacheva IA. Shikimic acid: review of its analytical, isolation, and purification techniques from plant and microbial sources. J Chem Biol 2012; 5:5-17. [PMID: 22826715 PMCID: PMC3251648 DOI: 10.1007/s12154-011-0064-8] [Citation(s) in RCA: 95] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2011] [Accepted: 07/14/2011] [Indexed: 11/26/2022] Open
Abstract
Shikimic acid properties and its available analytical techniques are discussed. Plants having the highest content of shikimic acid are shown. The existing isolation methods are analyzed and the most optimal approaches to extracting this acid from natural sources (plants and microorganisms) are considered.
Collapse
Affiliation(s)
- Denis V. Bochkov
- Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences (IPCET SB RAS), ul. Socialisticheskaya, 1, Biysk, 659322 Russia
| | - Sergey V. Sysolyatin
- Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences (IPCET SB RAS), ul. Socialisticheskaya, 1, Biysk, 659322 Russia
| | - Alexander I. Kalashnikov
- Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences (IPCET SB RAS), ul. Socialisticheskaya, 1, Biysk, 659322 Russia
| | - Irina A. Surmacheva
- Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences (IPCET SB RAS), ul. Socialisticheskaya, 1, Biysk, 659322 Russia
| |
Collapse
|
26
|
Navigating the human metabolome for biomarker identification and design of pharmaceutical molecules. J Biomed Biotechnol 2010; 2011. [PMID: 20936122 PMCID: PMC2948926 DOI: 10.1155/2011/525497] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2010] [Accepted: 07/12/2010] [Indexed: 12/31/2022] Open
Abstract
Metabolomics is a rapidly evolving discipline that involves the systematic study of endogenous small molecules that characterize the metabolic pathways of biological systems. The study of metabolism at a global level has the potential to contribute significantly to biomedical research, clinical medical practice, as well as drug discovery. In this paper, we present the most up-to-date metabolite and metabolic pathway resources, and we summarize the statistical, and machine-learning tools used for the analysis of data from clinical metabolomics. Through specific applications on cancer, diabetes, neurological and other diseases, we demonstrate how these tools can facilitate diagnosis and identification of potential biomarkers for use within disease diagnosis. Additionally, we discuss the increasing importance of the integration of metabolomics data in drug discovery. On a case-study based on the Human Metabolome Database (HMDB) and the Chinese Natural Product Database (CNPD), we demonstrate the close relatedness of the two data sets of compounds, and we further illustrate how structural similarity with human metabolites could assist in the design of novel pharmaceuticals and the elucidation of the molecular mechanisms of medicinal plants.
Collapse
|
27
|
PS3, A Semisynthetic β-1,3-Glucan Sulfate, Diminishes Contact Hypersensitivity Responses Through Inhibition of L- and P-Selectin Functions. J Invest Dermatol 2009; 129:1192-202. [DOI: 10.1038/jid.2008.358] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
|
28
|
Welch KT, Turner TA, Preast CE. Rational design of novel glycomimetics: Inhibitors of concanavalin A. Bioorg Med Chem Lett 2008; 18:6573-5. [DOI: 10.1016/j.bmcl.2008.09.095] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2008] [Revised: 09/24/2008] [Accepted: 09/26/2008] [Indexed: 11/30/2022]
|
29
|
Abdu-Allah HHM, Tamanaka T, Yu J, Zhuoyuan L, Sadagopan M, Adachi T, Tsubata T, Kelm S, Ishida H, Kiso M. Design, synthesis, and structure-affinity relationships of novel series of sialosides as CD22-specific inhibitors. J Med Chem 2008; 51:6665-81. [PMID: 18841881 DOI: 10.1021/jm8000696] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Sialosides incorporating substituted amides or amines at 9-position of sialic acid moiety have been synthesized and evaluated as CD22 inhibitors. Several derivatives exhibited inhibitory potency in sub- to low micromolar range (e. g., 8o, 9d, 9g, and 9k showed IC 50 values 0.40, 0.47, 0.24, and 0.23 microM, respectively, for hCD22, while 8p, 8q, and 9f, showed IC 50 values 1.70, 2.90, and 4.10 microM, respectively, for mCD22). The most significant result was the strongly enhanced affinity of 9g and 9k containing 9-(2' or 4'-hydroxy-4-biphenyl) methylamino substituents (600-fold more potent for hCD22 than the corresponding 9-hydroxy derivative; 7a). Molecular modeling study was carried out to get some insights into the molecular basis of CD22 inhibition. To the best of our knowledge, this is the first systematic structure-affinity relationship study on inhibition of CD22.
Collapse
Affiliation(s)
- Hajjaj H M Abdu-Allah
- Department of Applied Bio-organic Chemistry, The United Graduate School of Agricultural Sciences, Gifu University, Gifu 501-1193, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
von Itzstein M. Disease-associated carbohydrate-recognising proteins and structure-based inhibitor design. Curr Opin Struct Biol 2008; 18:558-66. [PMID: 18706999 DOI: 10.1016/j.sbi.2008.07.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2008] [Revised: 07/28/2008] [Accepted: 07/31/2008] [Indexed: 01/20/2023]
Abstract
The role of carbohydrate-related pathways in a wide range of clinically significant diseases has provided great impetus for researchers to characterise key proteins as targets for drug discovery. Carbohydrate-recognising proteins essential in the lifecycles of high health impact pathogens and diseases such as diabetes, cancer, autoimmunity, inflammation and in-born errors of metabolism continue to stimulate much interest in both structure elucidation and structure-based drug design. For example, advances in structure-based inhibitor design against the mycobacterial enzyme UDP-galactopyranose mutase offer new hope in next generation anti-tuberculosis chemotherapeutics. The appearance of H5N1 avian influenza virus has re-stimulated much research on influenza virus haemagglutinin and sialidase. These latest developments on influenza virus sialidase have provided new opportunity for the development of Group 1-specific anti-influenza drugs. The role of siglecs and galectins in a range of disease processes such as inflammation, apoptosis and cancer progression has also inspired significant structure-based inhibitor design research.
Collapse
Affiliation(s)
- Mark von Itzstein
- Institute for Glycomics, Gold Coast Campus, Griffith University, Queensland 4222, Australia.
| |
Collapse
|
31
|
Woodside DG, Vanderslice P. Cell adhesion antagonists: therapeutic potential in asthma and chronic obstructive pulmonary disease. BioDrugs 2008; 22:85-100. [PMID: 18345706 DOI: 10.2165/00063030-200822020-00002] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Chronic obstructive pulmonary disease (COPD) and asthma are inflammatory diseases of the lung where a hallmark feature is excessive leukocyte infiltration that leads to tissue injury. Cell adhesion molecules (e.g. selectins and integrins) play a key role in cell trafficking, and in the lung they regulate leukocyte extravasation, migration within the interstitium, cellular activation, and tissue retention. All selectin family members (including L-selectin, P-selectin, and E-selectin) and many of the beta1 and beta2 integrins appear to be important therapeutic targets, as numerous animal studies have demonstrated essential roles for these cell adhesion molecules in lung inflammation. Not surprisingly, these families of adhesion molecules have been under intense investigation by the pharmaceutical industry for the development of novel therapeutics. Integrins are validated drug targets, as drugs that antagonize integrin alphaIIbbeta3 (e.g. abciximab), integrin alphaLbeta2 (efalizumab), and integrin alpha4beta1 (natalizumab) are currently US FDA-approved for acute coronary syndromes, psoriasis, and multiple sclerosis, respectively. However, none has been approved for indications related to asthma or COPD. Here, we provide an overview of roles played by selectins and integrins in lung inflammation. We also describe recent clinical results (both failures and successes) in developing adhesion molecule antagonists, with specific emphasis on those targets that may have potential benefit in asthma and COPD. Early clinical trials using selectin and integrin antagonists have met with limited success. However, recent positive phase II clinical trials with a small-molecule selectin antagonist (bimosiamose) and a small-molecule integrin alpha4beta1 antagonist (valategrast [R411]), have generated enthusiastic anticipation that novel strategies to treat asthma and COPD may be forthcoming.
Collapse
Affiliation(s)
- Darren G Woodside
- Department of Drug Discovery, Biological Sciences, Encysive Pharmaceuticals Inc., Houston, Texas, USA.
| | | |
Collapse
|
32
|
Palomo C, Aizpurua JM, Balentová E, Azcune I, Santos JI, Jiménez-Barbero J, Cañada J, Miranda JI. “Click” Saccharide/β-Lactam Hybrids for Lectin Inhibition. Org Lett 2008; 10:2227-30. [DOI: 10.1021/ol8006259] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Claudio Palomo
- Departamento de Química Orgánica-I, Universidad del País Vasco, Joxe Mari Korta R&D Center, Avda, Tolosa-72, 20018 San Sebastián, Spain, and Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu-9, 28040 Madrid, Spain
| | - Jesus M. Aizpurua
- Departamento de Química Orgánica-I, Universidad del País Vasco, Joxe Mari Korta R&D Center, Avda, Tolosa-72, 20018 San Sebastián, Spain, and Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu-9, 28040 Madrid, Spain
| | - Eva Balentová
- Departamento de Química Orgánica-I, Universidad del País Vasco, Joxe Mari Korta R&D Center, Avda, Tolosa-72, 20018 San Sebastián, Spain, and Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu-9, 28040 Madrid, Spain
| | - Itxaso Azcune
- Departamento de Química Orgánica-I, Universidad del País Vasco, Joxe Mari Korta R&D Center, Avda, Tolosa-72, 20018 San Sebastián, Spain, and Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu-9, 28040 Madrid, Spain
| | - J. Ignacio Santos
- Departamento de Química Orgánica-I, Universidad del País Vasco, Joxe Mari Korta R&D Center, Avda, Tolosa-72, 20018 San Sebastián, Spain, and Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu-9, 28040 Madrid, Spain
| | - Jesús Jiménez-Barbero
- Departamento de Química Orgánica-I, Universidad del País Vasco, Joxe Mari Korta R&D Center, Avda, Tolosa-72, 20018 San Sebastián, Spain, and Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu-9, 28040 Madrid, Spain
| | - Javier Cañada
- Departamento de Química Orgánica-I, Universidad del País Vasco, Joxe Mari Korta R&D Center, Avda, Tolosa-72, 20018 San Sebastián, Spain, and Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu-9, 28040 Madrid, Spain
| | - José Ignacio Miranda
- Departamento de Química Orgánica-I, Universidad del País Vasco, Joxe Mari Korta R&D Center, Avda, Tolosa-72, 20018 San Sebastián, Spain, and Centro de Investigaciones Biológicas, CSIC, Ramiro de Maeztu-9, 28040 Madrid, Spain
| |
Collapse
|
33
|
Meyer M, Beyer D, Vollhardt K, Woischwill C, Jilma B, Wolff G. The pharmacokinetics of subcutaneously injected bimosiamose disodium in healthy male volunteers. Biopharm Drug Dispos 2007; 28:475-84. [PMID: 17876866 DOI: 10.1002/bdd.574] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Bimosiamose is a novel synthetic pan-selectin antagonist developed for the treatment of acute and chronic inflammatory disorders. Therefore the pharmacokinetics of Bimosiamose disodium were studied in healthy male volunteers after single and multiple subcutaneous injections. A randomized, double-blind, placebo-controlled dose escalation trial was carried out. The subjects received subcutaneous injections of placebo or 100, 200 or 300 mg Bimosiamose disodium into the abdomen. Plasma and urine concentrations of Bimosiamose were determined. The maximum plasma concentration was 2.17+/-0.70 microg/ml and the AUC(0-infinity) 11.1+/-2.9 h microg/ml after the highest dose on day 1 (mean+/-SD). For the apparent clearance CL/f 28.7+/-7.3 l/h and the terminal half life t(1/2) 3.7+/-0.6 h were calculated. The mean residence time MRT(infinity) of 5.5 to 6.3 h for s.c. injection exceeded that after i.v. infusion due to an extended absorption time. For multiple dosing, constant pre-dose concentrations of about 20 ng/ml may be reached after two subsequent doses of 200 or 300 mg Bimosiamose disodium once daily. Almost 15% of the administered drug was excreted unchanged in urine. Moreover, Bimosiamose was well tolerated.
Collapse
Affiliation(s)
- Michael Meyer
- Revotar Biopharmaceuticals AG, Neuendorfstr. 24a, D-16761 Hennigsdorf, Germany.
| | | | | | | | | | | |
Collapse
|